Try our beta test site
158 studies found for:    "Clear cell renal cell carcinoma"
Show Display Options
Rank Status Study
1 Recruiting Study of Neoadjuvant Nivolumab in Patients With Non-metastatic Stage II-IV Clear Cell Renal Cell Carcinoma
Condition: Clear Cell Renal Cell Carcinoma
Intervention: Drug: Nivolumab
2 Completed Safety and Activity of G-202 in Patients With Clear Cell Renal Cell Carcinoma That Expresses PSMA
Condition: Clear Cell Renal Cell Carcinoma
Intervention: Drug: G-202
3 Recruiting Nivolumab and Stereotactic Ablative Radiation Therapy (SAbR) for Metastatic Clear Cell Renal Cell Carcinoma
Condition: Metastatic Clear Cell Renal Cell Carcinoma
Interventions: Drug: Nivolumab;   Radiation: SAbR
4 Completed Validation of a Predictive Nomogram of Response or Resistance to Targeted Therapies in Metastatic Clear Cell Renal Cell Carcinoma
Condition: Metastatic Clear Cell Renal Cell Carcinoma
Intervention: Drug: Sunitinib
5 Active, not recruiting
Has Results
Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)
Condition: Advanced or Metastatic (Medically or Surgically Unresectable) Clear-cell Renal Cell Carcinoma
Interventions: Biological: Nivolumab;   Drug: Everolimus
6 Recruiting SLM + Axitinib for Clear Cell RCC
Condition: Advanced Metastatic Clear Cell Renal Cell Carcinoma (CCRCC)
Interventions: Drug: Selenomethionine (SLM);   Drug: Axitinib
7 Recruiting Addition of X4P-001 to Nivolumab Treatment in Patients With Renal Cell Carcinoma
Condition: Clear Cell Renal Cell Carcinoma
Interventions: Drug: X4P-001;   Drug: Nivolumab
8 Completed Effect of Sorafenib on ccRCC Uptake of Radiolabeled Bevacizumab or cG250
Condition: Clear Cell Renal Cell Carcinoma
Interventions: Drug: Sorafenib;   Drug: 111Indium-bevacizumab;   Drug: 111Indium-cG250
9 Unknown  Neoadjuvant Sunitinib Treatment for Metastatic Clear Cell Renal Cell Carcinoma (RCC)
Conditions: Clear Cell Renal Cell Carcinoma;   Metastasis
Intervention: Drug: Sunitinib
10 Terminated Sorafenib in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
Conditions: Hereditary Clear Cell Renal Cell Carcinoma;   Kidney Cancer
Interventions: Drug: sorafenib tosylate;   Procedure: diffusion-weighted magnetic resonance imaging
11 Completed
Has Results
Bevacizumab, Erlotinib, and Imatinib in the Treatment of Advanced Renal Cell Carcinoma
Condition: Clear Cell Renal Cell Carcinoma
Interventions: Drug: Bevacizumab;   Drug: Erlotinib;   Drug: Imatinib
12 Recruiting Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer
Conditions: Clear Cell Renal Cell Carcinoma;   Stage IV Renal Cell Cancer
Interventions: Biological: Bevacizumab;   Other: Laboratory Biomarker Analysis;   Drug: Pazopanib Hydrochloride;   Other: Pharmacological Study
13 Recruiting A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma
Conditions: ccRCC;   RCC;   Kidney Cancer;   Clear Cell Renal Cell Carcinoma;   Renal Cell Carcinoma
Interventions: Drug: PART 1: PT2385 Tablets;   Drug: PART 2: PT2385 Tablets in combination with nivolumab;   Drug: PART 3: PT2385 Tablets in combination with cabozantinib
14 Recruiting Trial of X4P-001 in Patients With Advanced Renal Cell Carcinoma
Condition: Clear Cell Renal Cell Carcinoma
Interventions: Drug: X4P-001;   Drug: axitinib
15 Completed Investigating Patient Satisfaction With Oral Anti-Cancer Treatment
Condition: Clear Cell Renal Cell Carcinoma
Intervention:
16 Recruiting Value of Various Chemokines in the Detection and Follow up of RCC
Condition: Clear Cell Renal Cell Carcinoma
Intervention: Other: patients with renal cell carcinoma
17 Unknown  1st-line Activity of Dovitinib and Correlation With Genetic Changes in RCC
Condition: Clear Cell Renal Cell Carcinoma
Intervention: Drug: Dovitinib
18 Completed Phase II Study of Lutetium-177 Labeled Girentuximab in Patients With Advanced Renal Cancer
Condition: Metastatic Clear Cell Renal Cell Carcinoma
Intervention: Drug: Lu-177-DOTA-girentuximab
19 Terminated
Has Results
Vandetanib to Treat Advanced Kidney Cancer
Condition: Advanced Clear Cell Renal Carcinoma
Intervention: Drug: vandetanib
20 Recruiting High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy for Metastatic Renal Cancer
Condition: Metastatic Clear Cell Renal Cell Carcinoma
Interventions: Drug: IL-2;   Radiation: Stereotactic Ablative Body Radiation Therapy

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.